Your browser doesn't support javascript.
loading
Serum neurofilament light as a biomarker in progressive multiple sclerosis.
Kapoor, Raju; Smith, Kathryn E; Allegretta, Mark; Arnold, Douglas L; Carroll, William; Comabella, Manuel; Furlan, Roberto; Harp, Christopher; Kuhle, Jens; Leppert, David; Plavina, Tatiana; Sellebjerg, Finn; Sincock, Caroline; Teunissen, Charlotte E; Topalli, Ilir; von Raison, Florian; Walker, Elizabeth; Fox, Robert J.
Afiliação
  • Kapoor R; From the University College London (R.K.), United Kingdom; National Multiple Sclerosis Society (K.E.S., M.A.), New York; McGill University (D.L.A.), Montreal, Canada; Perron Institute (W.C.), Sir Charles Gairdner Hospital, Perth, Australia; University Hospital Vall d'Hebron (M.C.), Barcelona, Spain;
  • Smith KE; From the University College London (R.K.), United Kingdom; National Multiple Sclerosis Society (K.E.S., M.A.), New York; McGill University (D.L.A.), Montreal, Canada; Perron Institute (W.C.), Sir Charles Gairdner Hospital, Perth, Australia; University Hospital Vall d'Hebron (M.C.), Barcelona, Spain;
  • Allegretta M; From the University College London (R.K.), United Kingdom; National Multiple Sclerosis Society (K.E.S., M.A.), New York; McGill University (D.L.A.), Montreal, Canada; Perron Institute (W.C.), Sir Charles Gairdner Hospital, Perth, Australia; University Hospital Vall d'Hebron (M.C.), Barcelona, Spain;
  • Arnold DL; From the University College London (R.K.), United Kingdom; National Multiple Sclerosis Society (K.E.S., M.A.), New York; McGill University (D.L.A.), Montreal, Canada; Perron Institute (W.C.), Sir Charles Gairdner Hospital, Perth, Australia; University Hospital Vall d'Hebron (M.C.), Barcelona, Spain;
  • Carroll W; From the University College London (R.K.), United Kingdom; National Multiple Sclerosis Society (K.E.S., M.A.), New York; McGill University (D.L.A.), Montreal, Canada; Perron Institute (W.C.), Sir Charles Gairdner Hospital, Perth, Australia; University Hospital Vall d'Hebron (M.C.), Barcelona, Spain;
  • Comabella M; From the University College London (R.K.), United Kingdom; National Multiple Sclerosis Society (K.E.S., M.A.), New York; McGill University (D.L.A.), Montreal, Canada; Perron Institute (W.C.), Sir Charles Gairdner Hospital, Perth, Australia; University Hospital Vall d'Hebron (M.C.), Barcelona, Spain;
  • Furlan R; From the University College London (R.K.), United Kingdom; National Multiple Sclerosis Society (K.E.S., M.A.), New York; McGill University (D.L.A.), Montreal, Canada; Perron Institute (W.C.), Sir Charles Gairdner Hospital, Perth, Australia; University Hospital Vall d'Hebron (M.C.), Barcelona, Spain;
  • Harp C; From the University College London (R.K.), United Kingdom; National Multiple Sclerosis Society (K.E.S., M.A.), New York; McGill University (D.L.A.), Montreal, Canada; Perron Institute (W.C.), Sir Charles Gairdner Hospital, Perth, Australia; University Hospital Vall d'Hebron (M.C.), Barcelona, Spain;
  • Kuhle J; From the University College London (R.K.), United Kingdom; National Multiple Sclerosis Society (K.E.S., M.A.), New York; McGill University (D.L.A.), Montreal, Canada; Perron Institute (W.C.), Sir Charles Gairdner Hospital, Perth, Australia; University Hospital Vall d'Hebron (M.C.), Barcelona, Spain;
  • Leppert D; From the University College London (R.K.), United Kingdom; National Multiple Sclerosis Society (K.E.S., M.A.), New York; McGill University (D.L.A.), Montreal, Canada; Perron Institute (W.C.), Sir Charles Gairdner Hospital, Perth, Australia; University Hospital Vall d'Hebron (M.C.), Barcelona, Spain;
  • Plavina T; From the University College London (R.K.), United Kingdom; National Multiple Sclerosis Society (K.E.S., M.A.), New York; McGill University (D.L.A.), Montreal, Canada; Perron Institute (W.C.), Sir Charles Gairdner Hospital, Perth, Australia; University Hospital Vall d'Hebron (M.C.), Barcelona, Spain;
  • Sellebjerg F; From the University College London (R.K.), United Kingdom; National Multiple Sclerosis Society (K.E.S., M.A.), New York; McGill University (D.L.A.), Montreal, Canada; Perron Institute (W.C.), Sir Charles Gairdner Hospital, Perth, Australia; University Hospital Vall d'Hebron (M.C.), Barcelona, Spain;
  • Sincock C; From the University College London (R.K.), United Kingdom; National Multiple Sclerosis Society (K.E.S., M.A.), New York; McGill University (D.L.A.), Montreal, Canada; Perron Institute (W.C.), Sir Charles Gairdner Hospital, Perth, Australia; University Hospital Vall d'Hebron (M.C.), Barcelona, Spain;
  • Teunissen CE; From the University College London (R.K.), United Kingdom; National Multiple Sclerosis Society (K.E.S., M.A.), New York; McGill University (D.L.A.), Montreal, Canada; Perron Institute (W.C.), Sir Charles Gairdner Hospital, Perth, Australia; University Hospital Vall d'Hebron (M.C.), Barcelona, Spain;
  • Topalli I; From the University College London (R.K.), United Kingdom; National Multiple Sclerosis Society (K.E.S., M.A.), New York; McGill University (D.L.A.), Montreal, Canada; Perron Institute (W.C.), Sir Charles Gairdner Hospital, Perth, Australia; University Hospital Vall d'Hebron (M.C.), Barcelona, Spain;
  • von Raison F; From the University College London (R.K.), United Kingdom; National Multiple Sclerosis Society (K.E.S., M.A.), New York; McGill University (D.L.A.), Montreal, Canada; Perron Institute (W.C.), Sir Charles Gairdner Hospital, Perth, Australia; University Hospital Vall d'Hebron (M.C.), Barcelona, Spain;
  • Walker E; From the University College London (R.K.), United Kingdom; National Multiple Sclerosis Society (K.E.S., M.A.), New York; McGill University (D.L.A.), Montreal, Canada; Perron Institute (W.C.), Sir Charles Gairdner Hospital, Perth, Australia; University Hospital Vall d'Hebron (M.C.), Barcelona, Spain;
  • Fox RJ; From the University College London (R.K.), United Kingdom; National Multiple Sclerosis Society (K.E.S., M.A.), New York; McGill University (D.L.A.), Montreal, Canada; Perron Institute (W.C.), Sir Charles Gairdner Hospital, Perth, Australia; University Hospital Vall d'Hebron (M.C.), Barcelona, Spain;
Neurology ; 95(10): 436-444, 2020 09 08.
Article em En | MEDLINE | ID: mdl-32675076
Assuntos
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Biomarcadores / Proteínas de Neurofilamentos / Esclerose Múltipla Crônica Progressiva Tipo de estudo: Guideline / Prognostic_studies Limite: Humans Idioma: En Revista: Neurology Ano de publicação: 2020 Tipo de documento: Article País de publicação: Estados Unidos
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Biomarcadores / Proteínas de Neurofilamentos / Esclerose Múltipla Crônica Progressiva Tipo de estudo: Guideline / Prognostic_studies Limite: Humans Idioma: En Revista: Neurology Ano de publicação: 2020 Tipo de documento: Article País de publicação: Estados Unidos